ZAPI GROUP Launches New High-Voltage Capabilities at The Battery Show North America 2025
6.10.2025 16:00:00 EEST | Business Wire | Press release
ZAPI GROUP, a global leader in electrification technology, will unveil its latest advancements in charging solutions, designed to meet the evolving needs of OEMs and the broader electrification market at The Battery Show North America in Detroit on October 6-9.
At the show, ZAPI GROUP will introduce all-new high-voltage and high-power charging capabilities for OEMs designing a wide variety of industrial and mobility electrification solutions. The first two designs are liquid-cooled 7.2 kW and 22 kW on-board chargers for 400 V and 800 V battery packs. Samples for system fit and interoperability testing will be available soon.
“We are proud to announce new capabilities to engineer unique charging solutions for the most demanding environments across industries,” said Sarah MacKinnon, CEO at Delta-Q Technologies, a ZAPI GROUP company. “With modular features like integrated Power Line Communication modules, DC-DC converters, and advanced digital controls, these solutions aim to set a new standard for performance and adaptability. We are excited to give our OEM partners greater flexibility and more opportunities to design systems that meet their unique requirements.”
These new charging solutions, along with the Group’s expanded capabilities in autonomous navigation, safety and asset tracking, telematics, and collision avoidance, are the result of recent strategic acquisitions and further solidify the company’s position as a leading solutions provider.
Other new and complementary products on display will be the DCC3 converter, a compact and rugged DC/DC converter engineered for maximum flexibility across a range of construction applications, featuring native cybersecurity, and the ACH3 inverter, a third-generation high-voltage inverter with customizable control software for enhanced performance.
For more information and to preview the latest capabilities and solutions, please visit ZAPI GROUP at Booth #3011.
About ZAPI GROUP
ZAPI GROUP is engineering the transition to an all-electric future with a highly integrated product portfolio, including motion controllers, electric motors, and high-frequency battery chargers for application in full-electric and hybrid vehicles. We provide turnkey system integration, autonomous navigation software, and safety and asset tracking for fleet management. Our companies include Zapi, Schabmueller, Inmotion, Delta-Q, BlueBotics, ZIVAN, Best Motor, ZTP, Ubiquicom, 4e Consulting, and Stercom.
As a global electrification leader with deep systems experience, leading innovations, and an obsession with driving customers' success, ZAPI GROUP now counts more than 1,700 employees worldwide with a total annual revenue of more than 700 million US dollars. For more information, visit www.zapigroup.com.
View source version on businesswire.com: https://www.businesswire.com/news/home/20251006652036/en/
Contacts
Carley Gray, Communiqué PR
Phone: (206) 282-4923 ext. 114
Email: zapigrouppr@communiquepr.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
www.businesswire.com
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Barilla Opens Global Call for Startups Through Good Food Makers 202625.5.2026 12:47:00 EEST | Press release
Barilla Group has opened applications for the 2026 edition of Good Food Makers, its global open innovation program designed to co-develop and test new innovative solutions with startups and innovators inside real industrial environments. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260521973445/en/ Since its launch in 2019, the program has involved more than 1,100 startups from over 50 countries, leading to 26 pilot projects, with over 20 projects currently active thanks to the solutions developed by the program’s alumni. This highlights the program’s role as a concrete platform for industrial scalable innovation. The 2026 edition comes at a pivotal moment for the company, following the launch of BITE (Barilla Innovation & Technology Experience), the new innovation center dedicated to developing the next generation of food products. Within this inspiring premise, Good Food Makers confirms itself as one of the main levers f
JEOL: Sales Launch of the Laser SEM System “LazEdge”25.5.2026 11:16:00 EEST | Press release
JEOL Ltd. (President & CEO: Izumi Oi) has developed the “LazEdge”, an SEM system equipped with a laser processing system, and begins sales on May 25, 2026. Cross-section preparation instruments such as the focused ion beam system (FIB system), are widely used in science and technology fields across research institutes, universities, and industries. In recent years, demand is increasing for a system that can process large-areas at a high speed, while achieving high-quality of the processed surface. “LazEdge” is an instrument integrating JEOL’s SEM with the laser technology proprietary of Hamamatsu Photonics K.K., and enables laser processing inside the specimen chamber of the electron microscope. This system enables high-quality cross-section specimens produced through high-speed, large-area processing to be transferred seamlessly to subsequent analyses, such as SEM observation, elemental analysis, and crystal orientation analysis, without exposure to the external environment. As a resu
TFG-001, A Novel 3D Neural Microtissue Cell Therapy, Demonstrates Superior Functionality and Reinnervation for Parkinson’s Disease25.5.2026 09:00:00 EEST | Press release
TreeFrog Therapeutics, a regenerative medicine biotech company developing next-generation cell therapies, today announced that it will present new preclinical data on TFG-001 at the 7th World Parkinson’s Conference. TFG-001, a 3D neural microtissue cell therapy, demonstrated rapid dopamine release and extensive graft-derived reinnervation across multiple advanced translational Parkinson’s disease models—supporting its potential as a best-in-class candidate. The critical need for reinnervation in Parkinson's disease In Parkinson's disease, an estimated 60–80% of dopaminergic neurons are already lost before motor symptoms even appear. The nigrostriatal pathway degenerates, destroying the essential wiring that connects dopamine-producing neurons to movement control. While chemical dopamine replacements (like levodopa) can manage symptoms, they cannot restore the spatial precision, feedback loops, or dynamic regulation of a healthy brain network. To achieve true functional restoration, it
TFG-001, A Novel 3D Neural Microtissue Cell Therapy, Demonstrates Superior Functionality and Reinnervation for Parkinson’s Disease25.5.2026 09:00:00 EEST | Press release
TreeFrog Therapeutics, a regenerative medicine biotech company developing next-generation cell therapies, today announced that it will present new preclinical data on TFG-001 at the 7th World Parkinson’s Conference. TFG-001, a 3D neural microtissue cell therapy, demonstrated rapid dopamine release and extensive graft-derived reinnervation across multiple advanced translational Parkinson’s disease models—supporting its potential as a best-in-class candidate. The critical need for reinnervation in Parkinson's disease In Parkinson's disease, an estimated 60–80% of dopaminergic neurons are already lost before motor symptoms even appear. The nigrostriatal pathway degenerates, destroying the essential wiring that connects dopamine-producing neurons to movement control. While chemical dopamine replacements (like levodopa) can manage symptoms, they cannot restore the spatial precision, feedback loops, or dynamic regulation of a healthy brain network. To achieve true functional restoration, it
Galderma Receives U.S. FDA Approval for Differin ® Epiduo ® Acne Gel Prescription-to-OTC Switch22.5.2026 19:25:00 EEST | Press release
Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) use in ages 12 years and older, marking a significant Prescription-to-OTC transition in acne care. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260522074280/en/ The U.S. FDA approves Differin® Epiduo® Acne Gel Prescription-to-OTC switch This milestone represents yet another example of Galderma’s unique Integrated Dermatology strategy, demonstrating how proven innovations from its Therapeutic Dermatology portfolio can further strengthen its Dermatological Skincare offerings. The Prescription‑to‑OTC transition highlights Galderma’s scale and expertise in successfully commercializing dermatology innovations across the full spectrum of acne care. With the appro
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom